Pralsetinib, a new medicine approved by the US Food and Drug Administration, was prescribed for the first time outside the US at Boao Super Hospital on Sept 29, 2020. It was Lecheng's first new drug to get listed and applied synchronously with the world.

In the field of the precision treatment of lung cancer, Pralsetinib has made a major breakthrough and has a strong, long-lasting and extensive anti-tumor effect. It has shown high clinical efficacy and tolerability in patients with RET fusion NSCLC (non-small-cell lung cancer).